



# Investor Presentation Q2FY21

06-11-2020

# Disclaimer



*Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.*

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.

The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

# Cipla's efforts in combatting Covid-19

Delivering on our promise of  
*'Caring for life'*

## Patients

- ❖ **1.5 lakhs+** severe Covid-19 patients serviced with supply of Actemra®, Cipremi® and Ciplenza®
- ❖ **95,000+** patients supported via 24\*7 helpline for Covid-19 products
- ❖ Offered support for post-recovery of mild-to-moderate Covid-19 patients

## Physicians

- ❖ Teleconsultation support to **20,000+ doctors** to ensure safe and convenient healthcare access
- ❖ Engagement with **2.5 lakhs+ doctors** through virtual conferences and continuing medical education seminars
- ❖ Developing knowledge building platforms for healthcare professionals by partnering with leading universities

## Employees

- ❖ Continued work from home with several enabling programs for ensuring well-being, care and support
- ❖ 24\*7 ambulance and quarantine facility in India for select locations
- ❖ Doctor consultation facility
- ❖ Health Insurance with COVID care cover

# Strong demand, resilient operations and cost control drive Q2 performance



## Overall Revenues

**↑ 15%** (YoY Growth)    **↑ 16%** (QoQ Growth)

Robust performance across geographies

1

## India delivers growth across all lines of business

One India

**↑ 17%** YoY    **↑ 30%** QoQ

India Rx

5<sup>th</sup> consecutive quarter of market beating growth

India Gx

Strong demand across regions

CHL

2x growth YoY led by organic and transferred brands

2

## US business continues to strengthen

**US\$141mn** Q2FY21 Revenues    **↑ 5%** QoQ

Continued momentum in new launches

3

## South Africa delivers strong growth

SA  
**↑ 14%** YoY in ZAR Terms

Strong performance across private and tender businesses

**EBITDA Margin**    **23%** Q2FY21

**↑ 29%** (YoY Growth)    **↑ 12%** (QoQ Growth)

Sustained cost control

# Continued progress across our key strategic priorities

## One-India

- Continue to drive synergies across the three businesses
- Prescription growth 14% YoY; continued servicing with Covid products
- Continued strong demand and high order flow across regions in trade generics
- Healthy demand in consumer health brands transitioned from trade generic business
- Digital adoption and launch of Berok Zindagi 3.0




## South Africa & Emerging markets

- 3<sup>rd</sup> largest within the SA private market with 7.0% market share<sup>1</sup>; new brands significant growth driver
- OTC market share stood at 7.2%; 3<sup>rd</sup> overall and 1<sup>st</sup> in addressable market<sup>1</sup>
- Australia and focused DTMs<sup>2</sup> witnessing strong demand and achieving scale
- Establishing biosimilar franchise via partnerships across emerging markets

## US Generics

- Continue to build the US pipeline with differentiated products
- Continued momentum across new launches such as Albuterol, Esomeprazole oral suspension, DHE Nasal spray; Dimethyl Fumarate DR launched
- Focused R&D investments towards value accretive assets
- Continued investments in expanding capacity and developmental capabilities for global respiratory franchise

# Continued focus on maintaining balance sheet health with strong cash flow generation



- Strong governance set-up for cash and liquidity management
- Focused efforts on working capital management and improved cash flow generation
- **Net cash positive position** at September-20 end reflects strong balance sheet strength

# Financial Performance – Q2FY21

**Revenues** INR 5,038 Cr ↑ 15% YoY

**EBITDA** INR 1,177 Cr | 23.4% ↑ 29% YoY


## Q2 FY21 (Consolidated)

	Actuals (Rs Cr)	vs Q2 FY 20
Total Revenue from Operations	5,038	15%
EBITDA	1,177	29%
EBITDA % of revenue	23.4%	266 bps
PAT	665	41%
PAT % of revenue	13.2%	248 bps

**R&D** INR 226 Cr



*Focused R&D investments*

## Revenue<sup>1</sup> Break-up



<sup>1</sup> India includes Rx + Gx+ CHL; Others: Includes CNV business ; SAGA includes South Africa, Sub-Saharan Africa and Cipla Global Access; Figures have been rounded-off

# India (Rx + Gx+ CHL<sup>1</sup>): Consistent execution driving growth across businesses in India




## Key Business Highlights

- The **prescription business** grew **14%** YoY led by Covid portfolio, traction in chronic therapies coupled with a recovering hospital business partially offset by subdued seasonal triggers in acute therapies
- As per IQVIA<sup>2</sup>, outperformed the market in Respiratory, Inhalation and Urology while Cardiology reported strong double digit growth on a YoY basis
- **The trade generics business** delivered healthy growth for the quarter driven by strong demand and high order flow
- **Consumer health business:** H1FY21 revenue stood at INR 180+ crore; Strong demand in consumer brands post transfer from trade generics business.



# SAGA<sup>1</sup>: South Africa, Sub-Saharan Africa and Cipla Global Access



## South Africa Market

↑ **14% Q2 YoY**  
ZAR Terms

## South Africa Private

↑ **9% Q2 YoY**  
ZAR Terms

## South Africa Tender

↑ **28% Q2 YoY**  
ZAR Terms

### Key Business Highlights<sup>2</sup>

- Growth in the quarter driven by strong demand across prescription, OTC and tender business
- SSA and CGA report strong growth attributable to robust order book and supplies
- As per IQVIA<sup>2</sup>, 3<sup>rd</sup> largest pharmaceutical corporation in SA private market with 7.0% market share
- As per IQVIA<sup>2</sup>, OTC market share stood at 7.2%; maintained 3<sup>rd</sup> rank overall and 1<sup>st</sup> in addressable market; grew at 8.2% while market grew at 2.6%
- Exclusive partnership with Alvotech for commercialisation of 5 biosimilar candidates in immunology and oncology space

# North America: Growth driven by continued momentum in new launches




## Key Business Highlights

- Continued traction in new launches namely Albuterol, Esomeprazole oral suspension and DHE Nasal Spray supporting the base business; Launched dimethyl fumarate DR capsules
- Growth across government and institutional channel driven by portfolio expansion
- Largest TRx market share of ~84% in the Proventil market as per IQVIA week ending 2<sup>nd</sup> October 2020
- US business profitability trending close to company level in H1FY21

## Q2 Y-o-Y


\$ Mn



Healthy YoY growth adjusted for Cinacalcet in base

**↑ 5% QoQ**

# ANDA<sup>1</sup> Portfolio & Pipeline (As on 30<sup>th</sup> Sept 2020)




<sup>1</sup> Does not include Vet product ANDAs

<sup>2</sup> PEFPAR approved ANDAs can be commercialised in US

## Emerging Markets


\$ Mn



- Maintained scale with continued demand across all regions
- Remdesivir supplies commenced across multiple markets; Covid kits launched
- Continued focus on value generating DTM<sup>1</sup> markets

## Europe

\$ Mn



- Strong performance in key DTM<sup>1</sup> markets
- FPSM pMDI market share is ~20%<sup>2</sup> and Beclomethasone 10.7%<sup>2</sup> in UK

## API

\$ Mn



- Strong sales momentum and orderbook
- Continued traction with global seedings & lock-ins
- Higher margins driven by product mix and pricing

# Priorities for the coming quarters: Sustaining growth through the pandemic



1

## Digital adoption and resilient operations

- Adopting digital transformation for patient and channel connect to expand access and leverage demand patterns
- Proactively de-risking the business by diversifying sources for critical APIs, intermediates and KSMs and maintaining adequate inventory levels

2

## Driving profitable growth

- **One-India:** Driving market beating growth and scaling India across the three businesses
- **South Africa:** Continue market outperformance in the private market & OTC portfolio with new launch momentum
- **US:** Drive share and focus on maximizing value opportunity in complex generics
- **Respiratory:** Continue focus on expanding our global respiratory franchise
- **Emerging Markets:** Focus on growth through organic launches and partnerships to augment generic and biosimilar footprint
- Drive Return on Invested Capital expansion

3

## Quality and Compliance

- Continue to engage with US FDA to comprehensively address observations in Goa
- Continue to operate our facilities globally with the highest level of compliance and control

# Thank you

## **Registered Office :**

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

For any queries, please contact

**Naveen Bansal**

[Investor.Relations@cipla.com](mailto:Investor.Relations@cipla.com)

For more information please visit

[www.cipla.com](http://www.cipla.com)